Ask HopeStage to review this study with me
Study ID: NCT03230097. We help you review the study, but cannot decide medical eligibility.
TerminatedNCT03230097
This Study Tests Whether BI 409306 Prevents people with a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
This study has public registry information in the United States, in Canada, in the United Kingdom, .... It focuses on Psychotic Disorders.
SchizophreniaOtherFrom 16 Years to 30 Years
Key information made simple
What is this study testing?
This study is testing whether the study approach may be useful for people experiencing schizophrenia.
What would participation involve?
Participants may complete study activities around the study approach, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Canada, China, United Kingdom.
Who is it mainly for?
This study appears to be mainly for people with schizophrenia.
What should you check before joining?
Ask about whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a hospital, with sites including ProScience Research Group in Culver City, University of California San Diego, and PRIME Clinic in New Haven. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually matching the main diagnosis and being able to understand the study and consent. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: September 29, 2017
- Recruitment status
- Terminated
- Estimated enrollment
- Not clearly listed
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- United States, Canada, United Kingdom, ...
- Age range
- From 16 Years to 30 Years
- Official registry ID
- NCT03230097
- Official title
- This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT03230097. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may help improve understanding of your condition.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in Canada.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 16 Years to 30 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Boehringer Ingelheim, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT04109950
Safety study of an Investigational Drug in schizophrenia
This study has public registry information in the United States, in Bulgaria, in Colombia, .... It is testing an Investigational Drug for schizophrenia.
TerminatedNCT04825860
SEP-363856 for schizophrenia
This study has public registry information in China, in Japan, in Philippines, .... It is testing SEP-363856 for schizophrenia.
TerminatedNCT01328093
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
This study has public registry information. It focuses on schizophrenia and currently lists study information in Austria, Belgium, France, Germany, Poland, the United States, Romania, Spain, and Sweden.